Literature DB >> 2118299

Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction.

G I Barbash1, A Roth, H Hod, M Modan, H I Miller, S Rath, Y H Zahav, G Keren, M Motro, A Shachar.   

Abstract

Although both the European Cooperative Study Group and the Thrombolysis in Myocardial Infarction IIB trial indicated that angiography and angioplasty as routine measures after thrombolytic treatment do not improve clinical outcome in patients with acute myocardial infarction, the potential benefit of angioplasty may have been negated by the fact that the procedure was performed too soon (less than 32 hours) after admission. A similar study was designed in which delayed invasive treatment was compared with conservative treatment in 201 patients with acute myocardial infarction given recombinant tissue-type plasminogen activator. The 97 patients randomized to the invasive group underwent routine coronary angiography and angioplasty 5 +/- 2 days after thrombolytic therapy, whereas the 104 patients randomized to the conservative group underwent angiography only for recurrent postinfarction angina or exercise-induced ischemia. Baseline characteristics of both groups were similar. In the invasive group, 92 patients underwent angiography, 49 angioplasty and 11 coronary artery bypass surgery. In the conservative group, 40 patients experienced early ischemia, 39 underwent angiography, 20 angioplasty and 4 coronary artery bypass surgery. Reinfarction rate and preservation of left ventricular function at discharge or 8 weeks after discharge did not differ in the 2 groups. Total mortality after a mean follow-up of 10 months was 8 of 97 in the invasive and 4 of 104 in the conservative groups (p = 0.15). However, if only patients who died after the timing of the scheduled protocol catheterization in the invasive arm were included, mortality was 5 of 94 and 0 of 100 in the invasive and conservative treatment groups, respectively (p = 0.02). (ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2118299     DOI: 10.1016/0002-9149(90)90478-j

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Treating myocardial infarction in the post-GUSTO era. A European perspective.

Authors:  M J de Boer; F Zijlstra
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

2.  Health related quality of life after conservative or invasive treatment of inducible postinfarction ischaemia. DANAMI study group.

Authors:  O S Mortensen; J K Madsen; T Haghfelt; P Grande; K Saunamäki; S Haunsø; E Hjelms; H Arendrup
Journal:  Heart       Date:  2000-11       Impact factor: 5.994

3.  Prognostic significance of nonfatal myocardial reinfarction in survivors of a first infarction.

Authors:  R T van Domburg; J W Deckers; P F M M van Bergen; A J Azar; J J C Jonker; M L Simoons
Journal:  Neth Heart J       Date:  2001-08       Impact factor: 2.380

4.  Routine Coronary Arteriography Following Thrombolytic Therapy for Acute Myocardial Infarction: An Unsettled Controversy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-07       Impact factor: 2.300

5.  Does aggressive care following acute myocardial infarction reduce mortality? Analysis with instrumental variables to compare effectiveness in Canadian and United States patient populations.

Authors:  Christine A Beck; John Penrod; Theresa W Gyorkos; Stan Shapiro; Louise Pilote
Journal:  Health Serv Res       Date:  2003-12       Impact factor: 3.402

Review 6.  Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.

Authors:  J C Gillis; A J Wagstaff; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

7.  Impact of on-site cardiac catheterization on resource utilization and fatal and non-fatal outcomes after acute myocardial infarction.

Authors:  Abdul R Halabi; Christine A Beck; Mark J Eisenberg; Hugues Richard; Louise Pilote
Journal:  BMC Health Serv Res       Date:  2006-11-10       Impact factor: 2.655

8.  Outcomes research in the development and evaluation of practice guidelines.

Authors:  Louise Pilote; Ira B Tager
Journal:  BMC Health Serv Res       Date:  2002-03-25       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.